Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Maria Soler Nunez appointed as Chief Quality Officer
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Subscribe To Our Newsletter & Stay Updated
